Canakinumab

Evidence Level: L5

Predicted Indications: 10

Canakinumab
Canakinumab: From Cryopyrin-Associated Periodic Syndromes to Familial Mediterranean Fever

## Pharmacist Assessment Report

Canakinumab: From Cryopyrin-Associated Periodic Syndromes to Familial Mediterranean Fever

Note on indication choice: The top TxGNN hit (rank 1, hepatic infarction) has no supporting evidence. This report therefore leads with the best-supported prediction, familial Mediterranean fever (rank 6). The other candidates are summarized in the conclusion.

One-Sentence Summary

Canakinumab is an IL-1β-neutralizing antibody, originally approved for cryopyrin-associated periodic syndromes (CAPS). The TxGNN model predicts it may be effective for familial Mediterranean fever (FMF), with 7 registered canakinumab trials and more than 20 publications currently pointing in this direction. The trials are mostly in CAPS and related periodic fevers, so the FMF-specific evidence rests mainly on the literature.

Quick Overview

Item	Content
Original Indication	CAPS (familial cold autoinflammatory syndrome and Muckle-Wells syndrome, per the literature; the US license records contain no indication text)
Predicted New Indication	Familial Mediterranean fever, autosomal dominant
TxGNN Prediction Score	99.41%
Evidence Level	L1 as assigned in the Evidence Pack, but provisional (see the caveat below)
US Market Status	✓ Marketed
Number of NDAs	3 listed licenses (1 BLA, 2 entries without a license number)
Recommended Decision	Proceed with Guardrails

Caveat on L1: The Phase 3 trials listed below appear to be CAPS studies, not FMF studies. Their link to FMF is unverified. The FMF-specific support comes from a systematic review and meta-analysis, cohort studies and reviews. A strict reading would put the FMF evidence closer to L3 until an FMF-specific RCT is confirmed.

Why is This Prediction Reasonable?

Canakinumab is a fully human monoclonal antibody that neutralizes IL-1β signaling and suppresses inflammation. Detailed mechanism-of-action data are not available in DrugBank for this pack, but the literature describes this mechanism consistently. CAPS is driven by NLRP3 mutations that cause IL-1β overproduction, and canakinumab treats it by blocking that cytokine.

FMF is also an IL-1β-driven autoinflammatory disease. It is caused by gain-of-function MEFV mutations affecting pyrin, a regulator of IL-1β activation. Colchicine is first-line therapy. Roughly 40% of patients respond only partially and 5–10% do not respond, so IL-1 blockade is a logical option for colchicine-resistant or colchicine-intolerant patients. Published reports cover canakinumab in this setting, including pediatric cohorts, withdrawal strategies, and use with or without colchicine.

Clinical Trial Evidence

None of the trial records below is confirmed as an FMF trial. They support the class effect and long-term safety of canakinumab in autoinflammatory disease.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00685373	Phase 3	Completed	166	Long-term safety and efficacy of canakinumab in CAPS (FCAS, MWS, NOMID)
NCT00465985	Phase 3	Completed	35	Three-part study with a randomized, double-blind, placebo-controlled withdrawal phase in Muckle-Wells syndrome
NCT00991146	Phase 3	Completed	19	Open-label 24-week efficacy and safety study in Japanese CAPS patients, with an extension phase
NCT01302860	Phase 3	Completed	17	One-year open-label study in CAPS patients aged 4 years or younger, including childhood vaccination response
NCT01576367	Phase 3	Completed	17	Open-label extension for long-term safety and efficacy in young CAPS patients
NCT01242813	Phase 2	Completed	20	Four-month open-label canakinumab treatment in TRAPS, with 6-month follow-up
NCT06838143	N/A	Recruiting	25	Real-world observational study (REASSURE) of Ilaris in hereditary periodic fevers (including colchicine-resistant FMF) and sJIA; no results yet

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37769252	2024	Systematic review and meta-analysis	Rheumatology (Oxford)	Qualitative and quantitative evidence on anti-IL-1 treatment in colchicine-unresponsive or colchicine-intolerant FMF
35874710	2022	Systematic review	Front Immunol	Safety and efficacy of IL-1 blockers (anakinra, canakinumab, rilonacept) across immune-mediated disorders
29768139	2018	Classified as Review in the pack	N Engl J Med	Canakinumab in FMF, mevalonate kinase deficiency and TRAPS; it may be the pivotal trial report, so verify before citing
28362189	2017	Review / trial report	Expert Rev Clin Immunol	Canakinumab for FMF patients with inadequate response to, or intolerance of, colchicine
40040547	2025	Cohort	Int J Rheum Dis	Compares attack features, acute-phase reactants and renal outcomes with canakinumab with or without colchicine
34568239	2021	Retrospective study	Front Pediatr	65 colchicine-resistant or colchicine-intolerant FMF patients on canakinumab for at least 6 months; dosing every 4 weeks
31463794	2019	Retrospective, single center	Paediatr Drugs	Experience with canakinumab in pediatric FMF unresponsive to colchicine
36961326	2023	Retrospective study	Rheumatology (Oxford)	Feasibility of canakinumab tapering and withdrawal in pediatric colchicine-resistant FMF
36062765	2022	Review	Clin Exp Rheumatol	Clinical outcomes and expectations of IL-1 inhibition in FMF
27603969	2016	Review	Expert Opin Biol Ther	Rationale for anti-IL-1 agents in colchicine-resistant FMF, based on pyrin regulation of IL-1β activation

US Market Information

Authorization Number	Product Name	Dosage Form	Manufacturer
BLA 125319	Ilaris	Injection, solution	Novartis Pharmaceuticals Corporation
No number listed	GUNA-ANTI IL 1	Solution / drops	Guna spa
No number listed	GUNA-HEMORRHOIDS	Solution / drops	Guna spa

Ilaris is the only entry with a real license number, and it is a BLA, not an NDA. The two Guna drop products have no license number and appear to be a different product category from the injectable antibody. None of the entries includes approved indication text.

Safety Considerations

Drug Interactions: No interaction records were found in the database query.

Please refer to the package insert for warnings and contraindications. That information is missing from this Evidence Pack and blocks a formal safety screen.

Guardrail from the pack’s assessment: monitor for infection risk during IL-1 blockade.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: FMF is a plausible IL-1-driven target for a marketed IL-1β blocker. The supporting literature includes a meta-analysis of anti-IL-1 therapy in FMF and several canakinumab cohorts in colchicine-resistant patients. However, the listed Phase 3 trials are CAPS studies, and the L1 grade is provisional.

Guardrails:

Colchicine stays first-line, and IL-1 blockade is considered only for colchicine-resistant or colchicine-intolerant patients.
Monitor for infections.

To proceed, the following is needed:

Confirmation of whether PMID 29768139 is the FMF-relevant pivotal RCT, and of any FMF-specific NCT records.
The package insert (warnings, contraindications, interactions) to complete the safety screen.
Approved indication text for the US licenses.
Route compatibility assessment, which is still pending.

Other candidates:

Blau syndrome (rank 8, L3): only case-level and pooled retrospective evidence, so it stays a research question.
Periodic fever-infantile enterocolitis-autoinflammatory syndrome (rank 5, L4): only indirect class-level evidence, so it stays a research question.
Hepatic infarction, hepatic veno-occlusive disease, peliosis hepatis, syndrome with combined immunodeficiency, extracutaneous mastocytoma, monosomy X and liver angiosarcoma: no supporting evidence, so each stays on Hold. Hepatic infarction, monosomy X and liver angiosarcoma have no plausible mechanistic link.

This report is for research reference only and is not medical advice. Repurposing candidates require clinical validation before any use.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.